This data and the rebound effect on tumor growth observed in preclinical cancer models and in other cancers after discontinuation of anti-VEGF therapy have led to the hypothesis that survival benefits from bevacizumab may depend on maintenance therapy [9–14]. Here, VEGFA is linked to cancer.